An international, randomized, double-blind, placebo-controlled, study of valacyclovir for the suppression of herpes simplex virus type 2 genital herpes in newly diagnosed patients
| Autor: | Kenneth H, Fife, Terri J, Warren, Scott E, Justus, Catherine K, Heitman |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Microbiology (medical)
Sexually transmitted disease Adult Male medicine.medical_specialty Canada Adolescent Herpesvirus 2 Human Placebo-controlled study Acyclovir Administration Oral Dermatology Placebo medicine.disease_cause Antiviral Agents law.invention Randomized controlled trial Double-Blind Method law Recurrence Internal medicine medicine Humans Chile Herpes Genitalis Aged First episode business.industry Public Health Environmental and Occupational Health Valine Middle Aged United States Surgery Valaciclovir Infectious Diseases Herpes simplex virus Treatment Outcome Valacyclovir Female business Brazil medicine.drug |
| Zdroj: | Sexually transmitted diseases. 35(7) |
| ISSN: | 0148-5717 |
| Popis: | BACKGROUND: Antiviral suppressive therapy of genital herpes is often initiated based on the established pattern of recurrences in an individual. Because most persons with first episode herpes simplex virus type 2 (HSV-2) infection experience recurrences and because viral shedding occurs frequently in the first year after infection we examined the strategy of initiating suppressive therapy shortly after diagnosis of genital HSV-2 infection. SUBJECTS AND METHODS: From June 16 2004 to July 26 2006 384 subjects from 74 sites in the United States Canada Argentina Brazil and Chile who were newly diagnosed with a first recognized episode of genital herpes at the time of the screening visit or within 3 months before the screening visit were randomized (2:1) to receive valacyclovir 1 g once daily or placebo for 24 weeks. Subjects were instructed to return to clinic during suspected genital herpes outbreaks for clinician confirmation of recurrences. RESULTS: Valacyclovir significantly prolonged the time to first recurrence of HSV-2 genital herpes in newly diagnosed subjects compared with placebo with approximately 43% of subjects on placebo and 71% of subjects on valacyclovir recurrence-free at 24 weeks (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|